Xisomab 3G3 for the Prevention of Catheter-Associated Thrombosis in Patients With Cancer Receiving Chemotherapy

Phase 2 Terminated 9 enrolled OHSU Knight Cancer Institute National Heart, Lung, and Blood Institute (NHLBI) · collab Oregon Health and Science University · collab

NaSingle-groupOpen-labelSupportive care

Summary

This phase II trial studies how well xisomab 3G3 works in preventing catheter-associated blood clots (thrombosis) in patients with cancer receiving chemotherapy. Many patients with cancer develop blood clots from their catheters and can have pain, swelling, and other symptoms. They also often require blood thinners, which can increase the risk of bleeding. Xisomab 3G3 is type of drug called a monoclonal antibody that may prevent blood clots caused by a catheter in patients receiving chemotherapy.

Timeline

Start: 2021-02-25
Primary completion: 2021-10-05
Completion: 2021-11-05

Outcome

Outcome not reported

Stopped (Enrollment): “Insufficient accrual rate”

Publications

Pfeffer MA, Kohs TCL, Vu HH, Jordan KR, Wang JSH, Lorentz CU, Tucker EI, Puy C, Olson SR, DeLoughery TG, Hinds MT, Keshari RS, Gailani D, Lupu F, McCarty OJT, Shatzel JJ. Factor XI Inhibition for the Prevention of Catheter-Associated Thrombosis in Patients With Cancer Undergoing Central Line Placement: A Phase 2 Clinical Trial. Arterioscler Thromb Vasc Biol. 2024 Jan;44(1):290-299. doi: 10.1161/ATVBAHA.123.319692. Epub 2023 Nov 16.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Xisomab 3G3	Unknown	2 mg/kg	Intravenous